Center for Scientific Review; Notice of Closed Meetings, 53391 [2020-18929]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices
combination with other potential
immuno-oncology drugs.
This technology discloses the
composition of an ADC comprising a
drug conjugated to CD56-specific
monoclonal antibodies, m900 and
m906, or an antigen-binding fragment,
wherein the drug comprises a cytotoxic
agent, including but not limited to PBD,
and to methods of using the ADCs for
treating neuroblastoma, small-cell lung
cancer, multiple myeloma, acute
myeloid leukemia, NK–T lymphoma,
and neuroendocrine cancer. This notice
is made in accordance with 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: August 20, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2020–18988 Filed 8–27–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
VerDate Sep<11>2014
17:16 Aug 27, 2020
Jkt 250001
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Biochemistry and Biophysics
of Membranes Study Section.
Date: September 28–29, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nuria E. Assa-Munt, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164,
MSC 7806, Bethesda, MD 20892, (301) 451–
1323, assamunu@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Cancer Health Disparities.
Date: September 28–29, 2020.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ola Mae Zack Howard,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7806, Bethesda, MD 20892, (301) 451–
4467, howardz@mail.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Nuclear and
Cytoplasmic Structure/Function and
Dynamics Study Section.
Date: September 28–29, 2020.
Time: 11:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jessica Smith, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, jessica.smith6@nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Health Services Organization and Delivery
Study Section.
Date: September 29–30, 2020.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jacinta Bronte-Tinkew,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3164,
MSC 7770, Bethesda, MD 20892, (301) 806–
0009, brontetinkewjm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–19–
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
53391
264: Imaging, Biomarkers and Digital
Pathomics for the Early Detection of
Premetastatic Aggressive Cancer.
Date: September 29, 2020.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ileana Hancu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5116,
Bethesda, MD 20817, (301) 402–3911,
ileana.hancu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 24, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–18929 Filed 8–27–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group Health, Behavior, and Context
Subcommittee.
Date: October 19, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: NICHD/NIH, 6710B Rockledge
Drive, Bethesda, MD 20892 (Virtual/
Teleconference).
Contact Person: Kimberly L. Houston,
M.D., Scientific Review Officer, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, 6710B
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
[Notices]
[Page 53391]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18929]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Biological Chemistry and Macromolecular
Biophysics Integrated Review Group; Biochemistry and Biophysics of
Membranes Study Section.
Date: September 28-29, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nuria E. Assa-Munt, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164, MSC 7806, Bethesda, MD
20892, (301) 451-1323, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Cancer Health Disparities.
Date: September 28-29, 2020.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ola Mae Zack Howard, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192, MSC 7806, Bethesda, MD
20892, (301) 451-4467, [email protected].
Name of Committee: Cell Biology Integrated Review Group; Nuclear
and Cytoplasmic Structure/Function and Dynamics Study Section.
Date: September 28-29, 2020.
Time: 11:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jessica Smith, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, [email protected].
Name of Committee: Healthcare Delivery and Methodologies
Integrated Review Group; Health Services Organization and Delivery
Study Section.
Date: September 29-30, 2020.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jacinta Bronte-Tinkew, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3164, MSC 7770, Bethesda, MD
20892, (301) 806-0009, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-19-264: Imaging, Biomarkers and Digital Pathomics for the
Early Detection of Premetastatic Aggressive Cancer.
Date: September 29, 2020.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ileana Hancu, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5116, Bethesda, MD 20817, (301) 402-3911,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: August 24, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-18929 Filed 8-27-20; 8:45 am]
BILLING CODE 4140-01-P
